Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non ST-elevation Myocardial Infarction
Conditions
Non ST-elevation Myocardial Infarction
Trial Timeline
Apr 23, 2015 → Feb 9, 2017
NCT ID
NCT02406248About Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd) is a approved stage product being developed by AstraZeneca for Non ST-elevation Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT02406248. Target conditions include Non ST-elevation Myocardial Infarction.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02406248 | Approved | Completed |